Peripheral Vascular Disease Articles & Analysis
21 news found
“The funding we have secured will allow REVA to move forward with our pivotal clinical trial to support FDA approval of our MOTIV peripheral vascular scaffold as well as to obtain FDA clearance of our TyroSphere bioresorbable embolic bead technology.” REVA’s MOTIV device represents a unique breakthrough technology for the treatment of patients ...
End of study brings Robocath closer to commercializing R-One in China in 2023 149 patients enrolled over six months in four Chinese centers Results of first vascular robotics study on this scale in China will be published in March 2023 Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular ...
ByRobocath
A £1.1 million project to develop biodegradable stents for patients with severe vascular disease, which affects around one million people in the UK, has started thanks to Innovate UK funding. ...
Among the most innovative MedTech emerging companies, KLISBio is keen to deal-make and establish strong relations with active investors and paramount players in the life science and regenerative medicine space, aiming to contribute to the advancement of the whole industry with SILKBridge®, KLISBio’s first product in pipeline for peripheral nerve repair. ...
ByKLISBio
Significant challenges in treating peripheral nerve injuries persist within the domain of surgery and regenerative medicine, having a profound impact on patients’ quality of life. ...
ByKLISBio
Among the best innovators in orthopedics, biologics and regenerative medicine participating in CG Musculoskeletal Conference, KLISBio is open to expand its network and build strong relations with investors and industry leaders, in the attempt to move forward the current standard of care in peripheral nerve repair with SILKBridge®, KLISBio’s first product in pipeline for ...
ByKLISBio
Among the most innovative MedTech emerging companies, KLISBio is keen to deal-make and establish strong relations with active investors and paramount players in the life science and regenerative medicine space, aiming to contribute to the advancement of the whole industry with SILKBridge®, KLISBio’s first product in pipeline for peripheral nerve repair. ...
ByKLISBio
With the profound impact on patients’ quality of life, peripheral nerve injuries remain at the forefront of treatment challenges for orthopedic surgeons. ...
ByKLISBio
Among the company’s developing portfolio of products is SILKBridge®, a first-to-market, silk-based graft for peripheral nerve repair, which is anticipated to be available for clinical use in 2023. ...
ByKLISBio
Engineered silk materials provide a unique combination of outstanding biological and mechanical properties for a variety of clinical indications such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is needed. ...
ByKLISBio
Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, today announces the successful completion of the first coronary angioplasty in China assisted by its R-One™ robotic platform. ...
ByRobocath
In addition, Imperative Care’s wholly owned subsidiary Truvic is developing solutions for the treatment of peripheral vascular disease. Imperative Care and Truvic are based in Campbell, ...
Twenty-two diabetic patients with neuropathy, infection, open wounds, history of recurrent infection, nonhealing wounds, and or peripheral vascular disease, were included, and all were at-risk for surgical site infection (SSI) due to the sequelae of diabetes. ...
“Having these high-caliber professionals join our Board speaks to the potential of our programs in bringing more innovative technologies to market faster and meeting patients’ needs in the fields of stroke and peripheral vascular disease.” After a distinguished career of more than 20 years in investment banking, Holly Sheffield ...
The proceeds from the Series D financing will also be used to advance Truvic’s development and commercialization of novel technologies for the treatment of peripheral vascular disease. “We are grateful for the confidence our investors have placed in us through this major financing, which we believe will have a profound impact on our ...
Additionally, a high-quality paper published on April 19, 2021 in the journal Diabetic Medicine, entitled Topical oxygen therapy for diabetes-related foot ulcers: A systematic review and meta-analysis (https://onlinelibrary.wiley.com/doi/10.1111/dme.14585), from the team headed by Professor Golledge at the independent Queensland Research Centre for Peripheral ...
I have long had a passion for the importance of specifically designed and studied technology for peripheral vascular disease treatment,” stated Stacy Enxing Seng. ...
The addition of a new larger extremity-chamber to the company’s peripheral vascular disease (PVD) focused product line, allows for the application of TWO2 treatments for many more patients suffering from costly nonhealing chronic wounds. ...
The IOPS™ platform was invented as a way to address limitations in fluoroscopy, the present standard of care for image guidance in minimally-invasive vascular surgery, which depends heavily on radiation and toxic contrast dyes to provide a relatively low-fidelity 2-D image. ...
Jean-Claude Tardif’s research group from the Montreal Heart Institute, have partnered with the aim to develop a new biomarker for atherosclerosis diagnosis. Atherosclerosis is a disease in which plaque build-up results in thickening and hardening of the walls of the arteries. These structural changes can lead to a reduction of blood flow to the brain and other organs and ...